CTRI/2021/10/037266招募中未知
Safety and Effectiveness of Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in Indian Population - Patient Registry - SAPIEN 3
Advanced Cardiovascular Care Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients who are operable and at any risk for surgical valve replacement. (STS and EuroScore all-risk categories are included)
- •2. Patient with age more than 65 years with severe symptomatic calcific aortic stenosis requiring aortic valve replacement characterized by one or more of the following within 60 days prior to the index procedure: aortic valve area (AVA) < 0.8 cm,indexed AVA <0.5 cm square/m square, mean gradient > 40mmHg, or peak aortic jet velocity > 4.0m/sec.
- •3. Patients coming under New York Heart Association (NYHA) Functional Class II or greater
- •4. The patient or the patientââ?¬•s legal representative will be informed of the nature of the study, agrees to its provisions, and will provide written informed consent as approved by the EC of the respective clinical site.
- •5. The patient agrees to comply with all required post-procedure follow-up visits.
- •6. Native aortic valve annulus area between 273 mm square - 683 mm square as measured by CT scan.
- •7. Native aortic annulus diameter between 18.6 mm ââ?¬â?? 29.5 mm as measured by CT scan.
排除标准
- •1. Patients with the evidence of an acute myocardial infarction ââ?°Â¤ 1 month (30 days) before the intended treatment [(defined as Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ââ?°Â¥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].
- •2. Presence of aortic valve, which is congenital unicuspid or is noncalcified.
- •3. Presence of anomalous coronary artery that would interfere with proper placement of the valve.
- •4. Presence of mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+).
- •5. Any therapeutic invasive cardiac procedure, resulting in a permanent implant that is performed within 30 days of the index procedure. Implantation with a permanent pacemaker or implantable cardioverter-defibrillator (ICD) is not considered exclusion criteria.
- •6. Any patient with a balloon valvuloplasty (BAV) within 30 days of the procedure (unless BAV is a bridge to the procedure after a qualifying echocardiogram)
- •7. Patients who had suffered a stroke or transient ischemic attack (TIA) within 3 months (90 days) of the procedure.
- •8. Patient with Leukopenia (WBC < 3000 cell/mL), Acute Anemia (Hgb < 9 g/dL), Thrombocytopenia (Plt < 50,000 cell/mL)
- •9. Patient with renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy at the time of screening
- •10. Patients having untreated clinically significant coronary artery
- •disease requiring revascularization.
- •11. Patients in need of emergency interventional/surgical procedures within one-month (30 days) prior to the Transcatheter Aortic Valve Implantation (TAVI) procedure.
- •12. Patients having hypertrophic cardiomyopathy (HCM with myocardium more than 1.5cm without an identifiable cause) with or without obstruction
- •13. Patients having severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%
- •14. Patients with echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
- •15. Patients having active upper GI bleeding within 3 months (90 days) prior to the procedure.
- •16. Patients with a known contraindication or hypersensitivity to all anticoagulation regimens or inability to be anticoagulated for the study procedure.
- •17. Patients having estimated life expectancy < 12 months (365 days) due to carcinomas, chronic liver disease, chronic renal disease, or chronic end-stage pulmonary disease
- •18. Patients with significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick ( > 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe ââ?¬Å?unfoldingââ?¬? and tortuosity of the thoracic aorta.
- •19 Patients with Iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath
- •20. Patients currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
研究者
相似试验
已完成
不适用
Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 StudyAortic Valve DiseaseNCT01808287Edwards Lifesciences250
已完成
不适用
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese PopulationSymptomatic Aortic StenosisAortic RegurgitationAortic StenosisNCT03466918Edwards Lifesciences58
已完成
不适用
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7Symptomatic Severe Aortic StenosisNCT03222141Edwards Lifesciences583
已完成
不适用
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 IntermediateSymptomatic Severe Aortic StenosisNCT03222128Edwards Lifesciences1,074
进行中（未招募）
不适用
EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic StenosisHeart DiseasesAortic Stenosis, SevereNCT03042104Edwards Lifesciences901